Odyssey Health Inc. (formerly Odyssey Group International, Inc.) is a technology and asset acquisition company with a focus in the area of life saving medical solutions.
Odyssey’s novel pharmaceutical compound, PRV-002, is intended for the treatment of concussion. PRV-002 is a new chemical entity administered nasally with proven in-vivo efficacy and safety in concussion models. Pre-clinical results show significantly improved sensory motor function and significantly improved memory scores. The drug is currently in a Phase 1 human trial.
Beyond concussion, Odyssey envisions treating related brain injuries and neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and ALS, with other novel neurosteroids.
Odyssey’s medical devices in development include the CardioMap® and Save-a-Life Device®. The CardioMap® serves as a 30-second EKG machine with a cloud-based algorithm, which provides physicians a 3D map of a patient’s heart. This provides actionable information in real time. Save-A-Life® is a patented, handheld anti-choking device that creates a vacuum chamber in the mouth to dislodge obstructions. In the U.S., choking results in 100,000 annual ER visits and is the 4th leading cause of unintentional death. Save-A-Life® is easy to use by both adults and children and can be self-administered.
RedChip.com | 1-800-REDCHIP (733-2447)
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.
Odyssey Health, Inc. is a client of RedChip Companies, Inc. ODYY agreed to pay RedChip Companies, Inc., a $7,500 monthly cash fee, 45,000 shares of rule 144 stock, and 45,000 options, beginning in May 2022, for 5 months of RedChip investor awareness services.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.
Website Powered By © 2023 Redchip Companies, Inc.